Commercial immunoassays in biomarkers studies: Researchers beware!

Clinical Chemistry

Volumn 58, Issue 10, 2012, Pages 1387-1388

  Rifai, Nader ^a   Watson, Ian D ^b   Miller, W Greg ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAVEOLIN 1; EPITOPE; FILMIN B; IRISIN; MEPRIN; RADIOISOTOPE; RNA; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBODY DETECTION; CANCER RESEARCH; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; EDITORIAL; HEALTH CARE COST; HUMAN; IMMUNOASSAY; RADIOIMMUNOASSAY; REPRODUCIBILITY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS; RESEARCH;

EID: 84867009373     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.192351     Document Type: Editorial

References (6)

1. National Institutes of Health. Research Portfolio Online Reporting Tools (RePORT). http://report.nih.gov/ (Accessed June 2012).
2. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971- 83.
3. Smith RD. Mass spectrometry in biomarker application: from untargeted discovery to targeted verification, and implications for platform convergence and clinical application. Clin Chem 2012;58:528 -30.
4. Git A. A recipe for disaster. Nature 2012;484:429-40.
5. Linnet K, Boyd JC. Selection and analytical validation of methods - with statistical techniques. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular methods, 5th ed. Philadelphia: Elsevier Saunders; 2012. p 7-47.
6. Rozet E, Marini RD, Ziemons E, Boulanger B, Hubert P. Advances in validation, risk and uncertainty assessment of bioanalytical methods. J Pharm Biomed Anal 2011;55:848 -58.